{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:51:33Z","timestamp":1790553093926,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the \u2018Th2\u2019 cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We investigated the cellular and functional basis for how IL-4\/IL-13 regulates the IL-23\u2013IL-17 axis in entheseal stromal, myeloid and lymphocyte cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Immunohistochemistry was performed on healthy enthesis samples from patients undergoing elective spinal surgery to investigate entheseal tissue IL-4R expression and cytokine expression by intracellular flow cytometry for IL-4 and IL-13. Digested human enthesis samples were stimulated with lipopolysaccharide (LPS) for IL-23 induction, either alone or with IL-4 or IL-13. Enthesis fibroblasts were stimulated with TNF and IL-17 with and without IL-4 or IL-13 to assess the effect on CCL20 secretion. Synovial fluid samples from PsA patients were also analysed by ELISA for levels of IL-4 and IL-13.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The IL-4\/IL-13 receptor was present in both the peri-entheseal bone and enthesis soft tissue, and entheseal-derived T cells produced basal levels of IL-4, but not IL-13. Both IL-4 and IL-13 attenuated LPS-induced entheseal IL-23 production. IL-4 also downregulated secretion of TNF\/IL-17A-induced CCL20 from entheseal fibroblasts. Both IL-13 and IL-4 were also detectable in the synovial fluid of PsA patients. We also noted a seronegative inflammatory oligoarthritis whilst under dupilumab therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest a previously unknown protective role for IL-4\/IL-13 in entheseal induction of the IL-23\u2013IL-17 axis. These findings point towards a novel explanation for IL-13 pathway single nucleotide polymorphisms in PsA and also a molecular explanation for why anti-IL-4\/IL-13 therapy may induce musculoskeletal entheseal pathology as recently reported.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa568","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T15:02:14Z","timestamp":1597158134000},"page":"2461-2466","source":"Crossref","is-referenced-by-count":53,"title":["Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy"],"prefix":"10.1093","volume":"60","author":[{"given":"Charlie","family":"Bridgewood","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassem","family":"Sharif","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Department of Medicine \u2018B\u2019, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Freeston","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Leeds Teaching Hospitals NHS Trust"},{"name":"National Institute for Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benazir","family":"Saleem","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Russell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Watad","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Department of Medicine \u2018B\u2019, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almas","family":"Khan","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Loughenbury","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Rao","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Wittmann","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"National Institute for Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"National Institute for Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"2021051419004884900_keaa568-B1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2021051419004884900_keaa568-B2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2021051419004884900_keaa568-B3","first-page":"551","article-title":"Structure of and signal transduction through interleukin-4 and interleukin-13 receptors","volume":"1","author":"Murata","year":"1998","journal-title":"Int J Mol Med"},{"key":"2021051419004884900_keaa568-B4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"2021051419004884900_keaa568-B5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"2021051419004884900_keaa568-B6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"Wijs","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2021051419004884900_keaa568-B7","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1111\/jdv.16239","article-title":"Polyenthesitis during treatment with dupilumab for atopic dermatitis","volume":"34","author":"Ishibashi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021051419004884900_keaa568-B8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jdcr.2020.01.012","article-title":"Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis","volume":"6","author":"Varma","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2021051419004884900_keaa568-B9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/DER.0000000000000481","article-title":"Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis","volume":"30","author":"Fowler","year":"2019","journal-title":"Dermatitis"},{"key":"2021051419004884900_keaa568-B10","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/ard.2010.143123","article-title":"Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021051419004884900_keaa568-B11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021051419004884900_keaa568-B12","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1038\/s41467-018-06933-4","article-title":"Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis","volume":"9","author":"Cambr\u00e9","year":"2018","journal-title":"Nat Commun"},{"key":"2021051419004884900_keaa568-B13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.03.965","article-title":"Differential requirement for CCR6 in IL-23-mediated skin and joint inflammation","author":"Shi","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2021051419004884900_keaa568-B14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10067-019-04683-2","article-title":"Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis","volume":"39","author":"Girolimetto","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2021051419004884900_keaa568-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1755-1536-3-9","article-title":"Interleukins 4 and 13 modulate gene expression and promote proliferation of primary human tenocytes","volume":"3","author":"Courneya","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2021051419004884900_keaa568-B16","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1084\/jem.20071397","article-title":"Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model","volume":"204","author":"Hirota","year":"2007","journal-title":"J Exp Med"},{"key":"2021051419004884900_keaa568-B17","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.4049\/jimmunol.159.11.5687","article-title":"Suppression of collagen-induced arthritis by continuous administration of IL-4","volume":"159","author":"Horsfall","year":"1997","journal-title":"J immunol"},{"key":"2021051419004884900_keaa568-B18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1172\/JCI7739","article-title":"IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion","volume":"105","author":"Lubberts","year":"2000","journal-title":"J Clin Invest"},{"key":"2021051419004884900_keaa568-B19","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/eji.1830261020","article-title":"Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13","volume":"26","author":"Bessis","year":"1996","journal-title":"Eur J Immunol"},{"key":"2021051419004884900_keaa568-B20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23\u2013IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2021051419004884900_keaa568-B21","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021051419004884900_keaa568-B22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2461\/37935959\/keaa568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2461\/37935959\/keaa568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:07:11Z","timestamp":1696522031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/5\/2461\/6012797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2021,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa568","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,11,30]]}}}